Mavyret OverviewGlecaprevir/pibrentasvir (trade name Mavyret) is a combination drug containing glecaprevir (100 mg) and pibrentasvir (40 mg). In the United States, it was approved by the Food and Drug Administration in August 2017 for treatment of hepatitis C. References ^ "FDA approves Mavyret for Hepatitis C" (Press release). Food and Drug Administration. August 3, 2017. v t e RNA virus antivirals (primarily J05, also S01AD and D06BB) Hepatitis C NS3/4A protease inhibitors (–...
Read more Mavyret Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glecaprevir/pibrentasvir
Recent Mavyret Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
Glecaprevir + Pibrentasvir
- Tablet: 100mg + 40mg
NDC Database Records for Mavyret: (1 result)Sorted by National Drug Code
- 0074-2625 Mavyret Oral Tablet, Film Coated by Abbvie Inc.